The Vanguard Health Care Fund (Trades, Portfolio), which, as its name suggests, invests almost exclusively in health care companies, made five new buys in the fourth quarter, but its most significant transaction was the sale of its 4,716,539-share stake in Humana Inc. (HUM, Financial), a Louisville, Kentucky-based health insurance company.
Vanguard sold the stake for an average price of $175.36 per share. The divestiture had a -1.82% impact on Vanguard’s portfolio.
Larry Robbins (Trades, Portfolio) is Humana’s leading shareholder among the gurus with 7,486,029 shares in his portfolio. The stake is 5.05% of Humana’s outstanding shares and 6.25% of Robbins’ total assets.
Humana has a P/E of 19, a forward P/E of 16.6, a P/B of 2.4 and a P/S of 0.5. GuruFocus gives Humana a Financial Strength rating of 6/10 and a Profitability and Growth rating of 6/10.
Humana sold for $166.58 per share Wednesday.
Vanguard also sold its 1,589,200-share stake in Zimmer Biomet Holdings Inc. (ZBH, Financial), a Warsaw, Indiana-based medical device company, for an average price of $100.92 per share. The deal had a -0.32% impact on Vanguard’s portfolio.
HOTCHKIS & WILEY is Zimmer Biomet’s leading shareholder among the gurus with 2,444,917 shares in its portfolio. The stake is 1.2% of Zimmer Biomet’s outstanding shares and 0.92% of HOTCHKIS & WILEY’s total assets.
Zimmer Biomet has a P/E of 86.4, a forward P/E of 11.7, a P/B of 2 and a P/S of 3.3. GuruFocus gives Zimmer Biomet a Financial Strength rating of 4/10 and a Profitability and Growth rating of 7/10.
Zimmer Biomet sold for $97.07 per share Wednesday.
Vanguard raised its stake in Allergan PLC (AGN, Financial), a pharmaceutical company with offices in Dublin and New Jersey, by more than 19%. Vanguard acquired 1,771,420 shares for an average price of $298.52 per share. The transaction had a 1.1% impact on Vanguard’s portfolio.
Vanguard’s 10,962,347-share stake in Allergan is the largest stake among the gurus. It is 2.78% of Allergan’s outstanding shares and 6.81% of Vanguard’s total assets.
Allergan has a P/E of 35.3, a forward P/E of 14.4, a P/B of 1.5 and a P/S of 4.8. GuruFocus gives Allergan a Financial Strength rating of 6/10 and a Profitability and Growth rating of 7/10.
Allergan sold for $277.73 per share Wednesday.
Vanguard boosted its stake in UnitedHealth Group Inc. (UNH, Financial), a Minnetonka, Minnesota-based managed health care company, by more than 9%. Vanguard purchased 1,995,000 shares for an average price of $116.87 per share. The deal had a 0.47% impact on Vanguard’s portfolio.
The purchase hiked Vanguard’s stake to 23,462,000 shares. Vanguard is UnitedHealth’s largest shareholder among the gurus with a stake that is 2.46% of UnitedHealth’s outstanding shares and 5.49% of Vanguard’s total assets.
UnitedHealth has a P/E of 17.8, a forward P/E of 13.4, a P/B of 3.2 and a P/S of 0.8. GuruFocus gives UnitedHealth a Financial Strength rating of 7/10 and a Profitability and Growth rating of 8/10.
UnitedHealth sold for $112.7 per share Wednesday.
Vanguard hiked its stake in Aetna Inc. (AET, Financial), a Hartford, Connecticut-based managed health care company, by nearly 31%. Vanguard bought 2,058,900 shares for an average price of $108.03 per share. The transaction has a 0.44% impact on Vanguard’s portfolio.
Vanguard’s stake, now 8,746,789 shares, is the largest among the gurus. The stake is 2.51% of Aetna’s outstanding shares and 1.88% of Vanguard’s total assets.
Aetna has a P/E of 15.5, a forward P/E of 11.5, a P/B of 2.2 and a P/S of 0.6. GuruFocus gives Aetna a Financial Strength rating of 7/10 and a Profitability and Growth rating of 8/10.
Aetna sold for $101 per share Wednesday.
Vanguard raised its stake in Cigna Corp. (CI, Financial), a Bloomfield, Connecticut-based managed health care company, by more than 24%. Vanguard acquired 1,392,900 shares for an average price of $137.56 per share. The deal had a 0.41% impact on Vanguard’s portfolio.
The purchase lifted Vanguard’s stake to 7,105,831 shares. The stake is 2.76% of Cigna’s outstanding shares and 2.07% of Vanguard’s total assets. Dodge & Cox is Cigna’s leading shareholder among the gurus with 12,879,034 shares in its portfolio. The stake is 5% of Cigna’s outstanding shares and 1.75% of Dodge & Cox’s total assets.
Cigna has a P/E of 16.2, a forward P/E of 12.7, a P/B of 2.9 and a P/S of 0.9. GuruFocus gives Cigna a Financial Strength rating of 6/10 and a Profitability and Growth rating of 7/10.
Cigna sold for $132.55 per share Wednesday.
Vanguard reduced its stake in Perrigo Co. PLC (PRGO, Financial), a pharmaceutical company with offices in Dublin and Michigan, by more than 95%. Vanguard sold 3,239,132 shares for an average price of $153.61 per share. The transaction had a -1.1% impact on Vanguard’s portfolio.
Vanguard’s remaining stake of 170,000 shares is 0.12% of Perrigo’s outstanding shares and 0.05% of Vanguard’s total assets. Eric Mindich (Trades, Portfolio) is Perrigo’s leading shareholder among the gurus with a 2,986,851-share stake in the company. The stake is 2.04% of Perrigo’s outstanding shares and 8.18% of Mindich’s total assets.
Perrigo has a P/E of 146.5, a forward P/E of 13.2, a P/B of 2 and a P/S of 4.2. GuruFocus gives Perrigo a Financial Strength rating of 3/10 and a Profitability and Growth rating of 6/10.
Perrigo sold for $145.66 per share Wednesday.
Vanguard trimmed its stake in Sanofi SA (XPAR:SAN, Financial), a French pharmaceutical company, by more than 58%. Vanguard sold 3,311,296 shares for an average price of €83.92 (about $91.53 in U.S. currency) per share. The deal had a -0.68% impact on Vanguard’s portfolio.
Vanguard’s remaining stake is 2,389,715 shares, the largest among the gurus. The stake is 0.18% of Sanofi’s outstanding shares and 0.4% of Vanguard’s total assets.
Sanofi has a P/E of 20.6, a forward P/E of 12.9, a P/B of 1.7 and a P/S of 2.7. GuruFocus gives Sanofi a Financial Strength rating of 7/10 and a Profitability and Growth rating of 6/10.
Sanofi sold for €75.27 (about $82.10 in American dollars) per share Tuesday.
Vanguard reduced its stake in Pfizer Inc. (PFE, Financial), a New York-based pharmaceutical company, by more than 29%, selling 3,678,766 shares for an average price of $33.17 per share. The transaction had a -0.25% impact on Vanguard’s portfolio.
Vanguard’s remaining stake of 8,872,226 shares is 0.14% of Pfizer’s outstanding shares and 0.57% of Pfizer’s total assets. Pfizer’s leading shareholder among the gurus is James Barrow (Trades, Portfolio) with a stake of 54,274,453 shares. The stake is 0.88% of Pfizer’s outstanding shares and 2.62% of Barrow’s total assets.
Pfizer has a P/E of 22.3, a forward P/E of 10.7, a P/B of 2.8 and a P/S of 4. GuruFocus gives Pfizer a Financial Strength rating of 7/10 and a Profitability and Growth rating of 7/10.
Pfizer sold for $29.65 per share Wednesday.
Vanguard sliced its stake in CR Bard Inc. (BCR, Financial), a Murray Hill, New Jersey-based medical technology company, by more than 71%. Vanguard sold 557,959 shares for an average price of $187.31 per share. The deal had a -0.23% impact on Vanguard’s portfolio.
Vanguard’s remaining stake of 226,841 shares is 0.31% of CR Bard’s outstanding shares and 0.09% of Vanguard’s total assets. Donald Yacktman (Trades, Portfolio) is CR Bard’s leading shareholder among the gurus with a stake of 1,464,225 shares. The stake is 1.98% of CR Bard’s outstanding shares and 1.79% of Yacktman’s total assets.
CR Bard has a P/E of 109.1, a forward P/E of 18.1, a P/B of 9.4 and a P/S of 4.1. GuruFocus gives CR Bard a Financial Strength rating of 7/10 and a Profitability and Growth rating of 8/10.
CR Bard sold for $184.92 per share Wednesday.
Vanguard acquired a 5,800,000-share stake in Teva Pharmaceutical Industries Ltd. (TEVA, Financial), an Israeli pharmaceutical company, for an average price of $61.94 per share. The purchase had a 0.76% impact on Vanguard’s portfolio.
Vanguard’s stake is 0.68% of Teva Pharmaceutical’s outstanding shares and 0.76% of Vanguard’s total assets. John Paulson (Trades, Portfolio) is Teva’s leading shareholder among the gurus with a stake of 18,000,000 shares. The stake is 2.11% of Teva’s outstanding shares and 5.43% of Paulson’s total assets.
Teva Pharmaceutical has a P/E of 29.2, a forward P/E of 10.5, a P/B of 2.3 and a P/S of 2.6. GuruFocus gives Teva Pharmaceutical a Financial Strength rating of 6/10 and a Profitability and Growth rating of 6/10.
Teva Pharmaceutical sold for $60.11 per share Wednesday.
To view the portfolios of more gurus, visit the List of Gurus page. Not a premium member of GuruFocus? Try it free for 7 days.
